ERBB2 and adenocarcinoma: In the phase II SUMMIT study of neratinib for recurrent metastatic uterine cervix cancer (23), eligible patients had a likely pathogenic mutation in ErbB2. Thirteen (81%) of 16 patients had adenocarcinoma (23).